Close

Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 16c

August 9, 2022 7:52 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.92), $0.16 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $55.6 million versus the consensus estimate of $49.08 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

The Children's Investment Fund (TCI), Earnings